You are viewing the site in preview mode
Skip to main content
| |
All (n = 137)
|
Exercise (n = 52)
|
Control (n = 62)
|
|---|
|
Age (years)a
|
64 [41, 81]
|
65 [48, 81]
|
65 [41, 77]
|
|
Sex (male) n, (%)
|
115 (83.9)
|
45 (86.5)
|
50 (80.6)
|
|
BMIb (kg/m2)
|
28.7 (25.6, 31.6)
|
29.4 (25.6, 31.8)
|
28.3 (25.4, 31.5)
|
|
Duration of diabetes (years)
|
9 (5, 15)
|
11 (5, 15)
|
9 (5, 13)
|
|
Previous MIc, n (%)
|
62 (45.3)
|
20 (38.5)
|
31 (50.0)
|
|
Microvascular complicationsd
|
26 (19)
|
7 (13.5)
|
10 (16.1)
|
|
Advanced vascular diseasee, n (%)
|
85 (62.0)
|
28 (53.8)
|
40 (64.4)
|
|
Hypertension, n (%)
|
100 (73.0)
|
39 (75.0)
|
46 (74.2)
|
|
Current smokers, n (%)
|
23 (16.8)
|
9 (17.3)
|
9 (14.5)
|
|
HbA1c (%)
|
7.4 (6.8, 8.3)
|
7.4 (6.8, 8.4)
|
7.3 (6.8, 7.9)
|
|
Fasting blood glucose
|
8.1 (6.9, 9.8)
|
7.5 (6.7, 9.9)
|
8.0 (6.8, 9.6)
|
|
HOMA2-IRf
|
1.3 (0.7, 2.1)
|
1.1 (0.7, 1.9)
|
1.3 (0.7, 2.2)
|
|
Total cholesterol (mmol/L)
|
3.9 (3.4, 4.5)
|
3.8 (3.4, 4.3)
|
4 (3.3, 4.7)
|
|
Triglycerides (mmol/L)
|
1.4 (1.0, 1.9)
|
1.4 (1.1, 1.9)
|
1.4 (1.0, 1.9)
|
|
LDLg cholesterol (mmol/L)
|
2.0 (1.6, 2.6)
|
1.8 (1.5, 2.5)
|
2.1 (1.6, 2.7)
|
|
CRPh (mg/L)
|
2.6 (1.2, 5.0)
|
2.0 (0.9, 4.9)
|
2.4 (1.2, 5.0)
|
|
Medication
|
|
RAAS inhibitors, n (%)
|
97 (70.8)
|
34 (65.4)
|
46 (74.2)
|
|
Statins, n (%)
|
128 (93.4)
|
49 (94.2)
|
58 (93.5)
|
|
Metformin, n (%)
|
101 (73.7)
|
40 (76.9)
|
46 (74.2)
|
|
Sulfonylureas, n (%)
|
48 (35.0)
|
23 (44.2)
|
17 (27.4)
|
|
Gliptin, n (%)
|
17 (12.4)
|
6 (11.5)
|
11 (17.7)
|
|
Insulin, n (%)
|
26 (19.0)
|
10 (19.2)
|
12 (19.4)
|
|
Antiplatelet medication, n (%)
|
129 (94.2)
|
47 (90.4)
|
61 (98.4)
|
- Data are presented as median (25, 75 percentiles) if not stated otherwise
- aMedian [min, max]
- bBody mass index
- cMyocardial infarction
- dMicrovascular complications were defined as a history of nephron-, neuro- or retinopathy, and/or abnormal monofilament test and/or (micro-) albuminuria
- eAdvanced vascular disease was defined as patients having previous myocardial infarction and/or diabetic microvascular complications in addition to coronary artery disease
- fGlucose and insulin values were entered in the computer model to calculate HOMA2-IR
- gLow-density lipoprotein
- hC-reactive protein
